학술논문
Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
Document Type
Article
Author
Coelho, Luís; Falcão, Fatima; Póvoa, Pedro; Viegas, Erica; Martins, Antonio Pais; Carmo, Eduarda; Fonseca, Candida; Campos, Luis; Mansinho, Kamal; Carmo, Inês; Soares, Joana; Solano, Mariana; Mendes, Dina; Miranda, Ana Cláudia; Carvalho, Antonio; Mirco, Ana; Farinha, Helena; Aldir, Isabel; Correia, José
Source
Subject
*SARS-CoV-2
*COVID-19
*COVID-19 treatment
*HOSPITAL patients
*ADULT respiratory distress syndrome
*
*
*
*
Language
ISSN
2045-2322
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2. Remdesivir (RDV) and corticosteroids are used mainly in COVID-19 patients with acute respiratory failure. The main objective of the study was to assess the effectiveness of remdesivir with and without corticosteroids in the treatment of COVID-19 patients. We conducted a prospective observational study, including adult patients consecutively hospitalized with confirmed COVID-19 and acute respiratory failure. Patients were divided according to treatment strategy: RDV alone versus RDV with corticosteroids. The primary outcome was the time to recovery in both treatment groups. We included 374 COVID-19 adult patients, 184 were treated with RDV, and 190 were treated with RDV and corticosteroid. Patients in the RDV group had a shorter time to recovery in comparison with patients in the RDV plus corticosteroids group at 28 days after admission [11 vs. 16 days (95% confidence Interval 9.7–12.8; 14.9–17.1; p =.016)]. Patients treated with RDV alone had a shorter length of hospital stay. The use of corticosteroids as adjunctive therapy of RDV was not associated with improvement in mortality of COVID-19 patients. [ABSTRACT FROM AUTHOR]